NCT02483260

Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever

Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever)

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: U.S. Army Medical Research and Development Command · Federal
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Is ribavirin a therapeutic option for patients with a probable or suspected case of viral hemorrhagic fever?

Detailed description

To provide an intravenous ribavirin therapeutic option for patients with a probable or suspected case of viral hemorrhagic fever, specifically Crimean-Congo hemorrhagic fever or Lassa fever.

Conditions

• Viral Hemorrhagic Fever

Interventions

Type	Name	Description
DRUG	Ribavirin	1. Loading dose, 33 mg/kg (maximum dose: 2.64 g) 2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses) 3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses).

Timeline

• Start date: 2016-06-16
• Primary completion: 2027-10-01
• Completion: 2028-12-01
• First posted: 2015-06-26
• Last updated: 2025-06-27

Locations

1 site across 1 country: Germany